Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091637 · ClinicalTrials.gov registry record · Phase 3
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)
A Phase 3 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,745
- Enrollment target
NCT00091637 is a Phase 3 study that has completed, run by Procter and Gamble. The registered enrollment target is 5,745 participants.
The verdict
NCT00091637, a Phase 3 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,745 participants
- Enrollment target
Study Summary
In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.
Interventions
- DRUG Placebo infusion
- DRUG Pexelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,745 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091637
The ClinicalTrials.gov registry entry for NCT00091637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,745 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Procter and Gamble, which has 70 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo infusion is the first listed.
NCT00091637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091637 about?
NCT00091637 is a clinical study titled "Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)". In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to redu...
What is the current status of trial NCT00091637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,745 participants. The study started on 2004-04. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00091637?
The interventions under investigation include: Placebo infusion (DRUG), Pexelizumab (DRUG).
Who is sponsoring clinical trial NCT00091637?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.